Yervoy and Zelboraf

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using ipilimumab together with vemurafenib may increase the risk of liver problems. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration of vemurafenib with ipilimumab may potentiate the risk of hepatotoxicity. In a dose-finding clinical trial, grade 3 increases in transaminases with or without concomitant increases in total bilirubin occurred in 6 of 10 patients who received concurrent vemurafenib (960 mg or 720 mg twice a day) and ipilimumab (3 mg/kg).

MANAGEMENT: The safety and effectiveness of vemurafenib in combination with ipilimumab have not been established. Liver transaminases, alkaline phosphatase, and bilirubin should be monitored prior to initiation of vemurafenib treatment and monthly during treatment, or as clinically indicated. Laboratory abnormalities should be managed with dosage reduction, treatment interruption, or treatment discontinuation in accordance with the product labeling.

Yervoy

Generic Name: ipilimumab

Brand name: Yervoy

Synonyms: n.a.

What is Yervoy?

Zelboraf

Generic Name: vemurafenib

Brand name: Zelboraf

Synonyms: n.a.

What is Zelboraf?